Today Stories

WILMINGTON, N.C., May 12, 2022 - The PPD clinical research business of Thermo Fisher Scientific, the world leader in serving science, has been distinguished for industry leadership in digital and decentralized clinical trial solutions by Information Services Group (ISG), a leading global technology research and advisory firm. The business was recognized as an ISG Provider Lens Leader for its digital transformation services, including customer solutions for clinical development and patient engagement. This marks the second consecutive year the business has been acknowledged by ISG. In its 2021 ISG Provider Lens Life Sciences Digital Services Global Report, ISG recognized Thermo Fisher's clinical research business with a clinical development leader designation for its skill and dexterity in…

New partnership will provide physician training to drive improved diversity in clinical trials Training program is open to underrepresented groups including female, Black, Native American, Asian, South Asian, Hispanic and non-binary cardiologists Provides opportunities for underrepresented physicians to receive training on the clinical trials process, learn new skills, expand their networks and increase visibility with industry partners ABBOTT PARK, Ill., May 11, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a new partnership with Women as One to launch a new program designed to train more female and underrepresented physicians to pursue clinical trial research and help recruit clinical trial participants from historically underrepresented groups. Women as One is a nonpro…

Pfizer to commercialize NURTEC® ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need Expands Pfizer’s innovative Internal Medicine pipeline to drive enhanced growth through 2030 and beyond Biohaven common shareholders will receive $148.50 per Biohaven share in cash, plus 0.5 of a share of a new publicly traded company that retains Biohaven’s non-CGRP pipeline compounds (“New Biohaven”) Pfizer and Biohaven to hold analyst call at 10am ET today NEW YORK & NEW HAVEN, CONN.--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven, the maker of NURTEC® OD…

Arrangement Expands Labcorp’s Services to Patients and Providers in Southern New Jersey BURLINGTON, N.C., and EGG HARBOR TOWNSHIP, N.J.--(BUSINESS WIRE)--May 9, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, and AtlantiCare, the largest health care organization in southern New Jersey, today announced that they have closed a transaction to expand their long-term strategic relationship. Labcorp will acquire select assets from AtlantiCare’s clinical outreach business, which serves the AtlantiCare Physician Group and Affiliated Physicians and their patients across southern New Jersey. The transaction is the latest in a series of new and expanded collaborations between Labcorp and health systems across the country, demonstrating the value that Labcorp brings to improve labor…

INDIANAPOLIS--(BUSINESS WIRE)--Modular Devices Acquisition, LLC (Modular Devices), a leading provider of mobile cath labs and mobile cleanrooms, today announced the acquisition of Cardiac Services Mobile, Inc. (Cardiac Services Mobile), a mobile cath lab company out of Nashville, TN that serves the US markets. The acquisition builds on Modular Devices’ position as the premier provider of mobile cardiac cath, peripheral vascular, electrophysiology (EP) and mobile CT labs for the rapidly growing US mobile imaging market. Modular Devices, based in Indianapolis, IN, is a long-time driver of innovation in the mobile cath lab industry. The company’s imaging division provides a comprehensive fleet of temporary interim cath, IR, EP and CT labs serving the hospital, ambulatory surgery center (ASC)…

Acquisition to strengthen ADVANZ PHARMA’s position as a partner of choice for commercialisation of specialty and hospital pharmaceuticals in Europe Agreement includes ex-U.S. rights to commercialise orphan drug Ocaliva® for PBC, a progressive autoimmune disease affecting the liver, and the acquisition of the majority of Intercept’s subsidiaries and operations in Europe, Canada, and all other markets outside of the U.S. LONDON, May 05, 2022 /CNW/ - ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"), a UK-headquartered pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals in Europe, has signed an agreement with Intercept Pharmaceuticals, Inc. (“Intercept”) to acquire the majority of Intercept’s subsidiaries and operations in Europe, Canada, and…

The transaction capitalizes on the two company’s combined geographic strengths, complementary service offerings and therapeutic expertise to advance industry-leading research for improved patient outcomes. WILMINGTON, N.C., ALDERLEY PARK, U.K, 4 May 2022 – Today, Catalyst Clinical Research, a market-leading provider of clinical research services, announced a strategic acquisition of Aptus Clinical to expand the geographic reach of the two companies, and to enhance patient access to advanced, life-changing therapies. Together, the two entities will become one multi-region clinical research organization with an accelerated growth trajectory in both the U.S. and Europe. Catalyst’s offerings will now encompass extensive and expanded clinical consulting services, as it inherits Aptus’ strong an…

Rebranding comes after a series of strategic acquisitions, most recently Pharm-Olam Company’s newly combined services address clinical development and consulting needs of small and mid-sized biotechs New name unites worldwide experienced workforce in its singular mission CARY, N.C., May 3, 2022 – Global biopharmaceutical services leader, CATO SMS, today unveiled its new name, Allucent with bold branding to emphasize the company’s spotlight on serving the specialized needs of small and mid-sized biotech companies. This move follows a three-year series of strategic acquisitions*, most recently of clinical research provider, Pharm-Olam, that doubled the company’s size, strengthened and deepened its capabilities, and expanded its global reach. Now, Allucent is a unified organization with mor…

– Gilead to License Exclusive Worldwide Rights to the Investigational Candidate DF7001, a 5T4-Targeting NK Cell Engager for Solid Tumors – Gilead to Have Options to License Several Additional NK Cell Engager Programs FOSTER CITY, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Dragonfly Therapeutics today announced a collaboration designed to advance a number of Dragonfly's novel natural killer (NK) cell engager-based immunotherapies for oncology and inflammation indications. NK cell engagers represent a novel mechanism with the potential to address a broad range of cancers, including potential for activity in checkpoint resistant and refractory tumors, as well as other disease areas such as inflammation. Under the agreement, Gilead will receive an e…

Move brings together AstraZeneca and Alexion colleagues in a purpose-built facility in Kendall Square, Cambridge, MA, a world leading life sciences hub AstraZeneca today announced plans to open a new site at the heart of the Cambridge, MA, life sciences and innovation hub. The new site will be a strategic R&D centre for AstraZeneca, as well as Alexion’s new corporate headquarters. The site will bring together approximately 1,500 R&D, commercial and corporate colleagues into a single purpose-built space in Kendall Square, Cambridge, MA. The site, scheduled for completion in 2026, will be in close proximity to several major academic, pharma and biotech institutions, inspiring greater collaboration and innovation potential, and providing access to future talent. The move reinfor…

The three companies will work to accelerate development of automated insulin delivery system for people living with diabetes System is being designed to include Abbott's FreeStyle Libre® 3 sensor, CamDiab's CamAPS FX algorithm, and Ypsomed's mylife™ YpsoPump® Partnership demonstrates the companies' collective desire to drive integrated solutions to help people with diabetes better manage their condition and improve health outcomes BARCELONA, Spain, April 27, 2022 /PRNewswire/ -- Abbott (NYSE: ABT), CamDiab and Ypsomed today announced that they are partnering to develop and commercialize an integrated automated insulin delivery (AID) system to help lessen the burden of round-the-clock diabetes management for people with diabetes. The initial focus of the partnership will be in European co…

Groundbreaking “Make to Order” Process for Stem Cell Therapy Wins Supply Chain Category Vaccine Facility in Singen, Germany, Wins Pharma 4.0 Category for Applying Digital Technologies in Production Process Recognition Illustrates Takeda’s Patient-Centricity Throughout its Manufacturing and Supply Processes OSAKA, Japan and CAMBRIDGE, Massachusetts, April 26, 2022 – Takeda (TSE:4502/NYSE:TAK) today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company top honors in the Supply Chain and Pharma 4.0™ categories for the 2022 Facility of the Year Awards (FOYA). In the Supply Chain category, Takeda was awarded for its implementation of a new patient-focused supply chain for its allogeneic mesenchymal stem cell therapy; and Takeda’s vaccine pro…

Now available for use with both Apple and Android devices, the app helps people track pain relief during the treatment journey with neurostimulation devices Updated app provides doctors with an at-a-glance assessment of their patients while on their treatment journey ABBOTT PARK, Ill., April 25, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that it has launched an upgraded version of its NeuroSphere™ myPath™ digital health app with enhanced functionality that will help doctors more closely track their patients as they trial Abbott neurostimulation devices to address their chronic pain. This upgrade is part of Abbott's commitment to connected care technology and is intended to put people in control of their health and facilitate better communication with their doctors. The digit…

Collaboration Combines Labcorp’s Diagnostic Tests with Getlabs At-Home Phlebotomy Services Underscores Labcorp’s Commitment to Offer Consumers Choice, Convenience and Access to Health Care BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 22, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced the launch of Getlabs for Labcorp, an innovative health care service that combines Labcorp’s diagnostic tests with Getlabs phlebotomy service to conveniently test consumers in the comfort of their own homes. With the service, individuals can now schedule a home blood draw or specimen collection when it’s convenient for them. Appointments are available through Labcorp.com. Getlabs provides at-home lab appointments performed by its full-time phlebotomists and charges a convenienc…

WILMINGTON, N.C., April 21, 2022 - The PPD clinical research business of Thermo Fisher Scientific was named "Best Contract Research Organization" at the 15th annual Vaccine Industry Excellence (ViE) Awards during the 2022 World Vaccine Congress, recognizing its success in helping customers develop safe and effective vaccines to improve health and save lives. The honor marks the business' second consecutive year earning "Best CRO" at the ViE Awards and follows recognition at the Citeline Awards as "Clinical Research Team of the Year" with Moderna, whose pioneering mRNA vaccine for COVID has been administered to hundreds of millions globally. With more than 30 years of commercial and government vaccine experience, the business has conducted vaccine studies in more than 90 countries and works…

$44 million facility increases production of single-use bioprocess containers that are critical to the development of new vaccines and therapies OGDEN, Utah, April 20, 2022 - Thermo Fisher Scientific today celebrated the opening of its new single-use technology manufacturing site in Ogden, Utah. The state-of-the-art facility creates additional capacity to produce the high-quality technology and materials needed for the development of new vaccines and breakthrough therapies. The $44 million facility is part of Thermo Fisher's $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19. The Ogden site…

Mobile research – sites an innovative decentralized trial solution – ease barriers to patient participation, improve trial enrollment WILMINGTON, N.C., April 19, 2022 - The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, and Matrix Clinical Trials, a Matrix Medical Network offering, are collaborating to bring clinical trials to patients with an innovative decentralized clinical trial (DCT) solution. The business is deploying state-of-the-art Matrix mobile research sites and expert clinical staff across the U.S. to help identify, recruit and retain trial participants, while ensuring a positive patient experience. At the same time, the two companies are exploring opportunities to expand the collaboration to additional geographies. Therm…

The Citeline Award recognizes the COVE study, Moderna's Phase III vaccine trial that enrolled more than 30,000 participants across the U.S. WILMINGTON, N.C., April 14, 2022 - The PPD clinical research business of Thermo Fisher Scientific and Moderna, whose pioneering mRNA vaccine for COVID has been administered to hundreds of millions globally, were named "Clinical Research Team of the Year" during the 2021 Citeline Awards. As Moderna's clinical research organization partner, the PPD team, now part of Thermo Fisher, supported Moderna's mRNA-1273-P301 vaccine trials, including its pivotal Phase III COVE study. The study enrolled more than 30,000 participants, ages 18 and older, across 99 U.S. sites in 12 weeks in the summer/fall of 2020. The Citeline Award for "Clinical Research Team of t…

Sierra Oncology’s differentiated momelotinib has the potential to address the critical unmet medical needs of myelofibrosis patients with anaemia Momelotinib complements GSK’s existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022 Sales contribution expected to start in 2023 with significant growth potential thereafter Supports development of strong portfolio of new specialty medicines and vaccines GlaxoSmithKline plc (LSE/NYSE: GSK) and Sierra Oncology, Inc (Nasdaq: SRRA) today announced that the companies have entered into an agreement under which GSK will acquire Sierra Oncology, a California-based, late-stage biopharmaceutical company focused on targeted therapies for the treatment of…

Almac Sciences, a member of the Almac Group, today announces a £500,000 investment in NMR instrumentation at its global Headquarters, Craigavon, UK, marking an over £900,000 total investment in nuclear magnetic resonance (NMR) technology for the organisation since 2018. High-resolution NMR is a key enabling technology that delivers advanced characterisation and purity assessment abilities in line with regulatory requirements. The service helps deliver comprehensive solutions that support drug substance (API) and drug product development programs, from early phase to commercialisation. Almac’s investment includes the addition of a second 500MHz NMR system, which has been added to further expand the current service offerings within of Almac Sciences’ state-of-the-art cGMP facility. This will…